Mona Ashiya

JP Morgan's biotech analysts Cory Kasimov, Mona Ashiya, and Karen Jay rate Ariad Pharmaceuticals (NASDAQ: ARIA) Overweight. Ariad's updated Phase I results for new cancer drug AP-23534 were presented on 6/3, and were promising. There were no signals for safety issue either. Based on these results,...

J.P. Morgan analysts Cory Kasimov and Mona Ashiya reiterated their Overweight rating for shares of Human Genome Sciences, Inc. (Nasdaq: HGSI) The two analysts believed that the failure of a recent Phase 2 non-small cell lung cancer trial would not have a significant impact on Human Genome Sciences...